First patient successfully dosed in TRP 8803 BED trial
Filed with ASX · · 4 pages · English
• Successful and safe administration of TRP-8803 (IV-infused psilocin), with precise control over dose and duration, in first enrolled BED patient – Marks a world first clinical use of TRP-8803 in a neuropsychiatric condition • BED patient underwent a therapeutic mid-range dose infusion for 140 minutes, progressed well through treatment and was discharged on completion • Patient to now undergo sup
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- BED trial accelerates - enrolment grows, dosing in two weeks
- $6.1m in new funding to accelerate clinical development
- Trading Halt
- First patient enrolled in Binge Eating Disorder Trial
- Appendix 4E and 2025 Annual Report
Later from Entropy Neurodynamics
- First BED patient completes second TRP-8803 infusion
- $847,186 R&D Tax Incentive received
- TRP-8802 Phase 2a Trial Shows Sustained BED Reduction
- First TRP-8803 BED patient shows broad clinical improvement
- Quarterly Activities Report and Appendix 4C
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics